Pharmacological options for treatment of hyperandrogenic disorders

P. Reismann, I. Likó, P. Igaz, A. Patócs, K. Rácz

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7% in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5α-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5α-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.

Original languageEnglish
Pages (from-to)1113-1126
Number of pages14
JournalMini-Reviews in Medicinal Chemistry
Volume9
Issue number9
DOIs
Publication statusPublished - Nov 27 2009

    Fingerprint

Keywords

  • 5α-reductase inhibitors
  • Androgen excess
  • Androgen receptor antagonists
  • Antiandrogen therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this